IDEAYA Biosciences (NASDAQ:IDYA) Price Target Raised to $36.00
IDEAYA Biosciences (NASDAQ:IDYA – Free Report) had its price objective boosted by Royal Bank of Canada from $32.00 to $36.00 in a report published on Tuesday morning, Benzinga reports. The brokerage currently has an outperform rating on the stock. Several other equities analysts have also commented on the stock. SVB Leerink assumed coverage on shares […]
More Stories
Merck & Co., Inc. (NYSE:MRK) Holdings Raised by Capital International Inc. CA
Capital International Inc. CA increased its stake in Merck & Co., Inc. (NYSE:MRK – Free Report) by 164.7% during the...
Capital International Inc. CA Cuts Stake in Mondelez International, Inc. (NASDAQ:MDLZ)
Capital International Inc. CA lowered its stake in Mondelez International, Inc. (NASDAQ:MDLZ – Free Report) by 23.0% in the first...
CSX Co. (NASDAQ:CSX) Shares Acquired by Capital International Inc. CA
Capital International Inc. CA boosted its holdings in CSX Co. (NASDAQ:CSX – Free Report) by 15.3% during the first quarter,...
Capital Group Private Client Services Inc. Buys 3,047 Shares of Union Pacific Co. (NYSE:UNP)
Capital Group Private Client Services Inc. increased its holdings in Union Pacific Co. (NYSE:UNP – Free Report) by 7.2% during...
Kemira Oyj (OTCMKTS:KOYJF) Short Interest Update
Kemira Oyj (OTCMKTS:KOYJF – Get Free Report) saw a large growth in short interest during the month of July. As...
Short Interest in General Enterprise Ventures, Inc. (OTCMKTS:GEVI) Increases By 197.8%
General Enterprise Ventures, Inc. (OTCMKTS:GEVI – Get Free Report) saw a significant increase in short interest in the month of...